OBJECTIVE: To develop and validate a volume-based, quantitative imaging marker by integrating multi-parametric MR images for predicting @entity463 survival, and to investigate its relationship and synergy with molecular characteristics. METHODS: We retrospectively analysed 108 @entity1 with @entity463 . The discovery cohort consisted of 62 @entity1 from the @entity5 (TCGA). Another 46 @entity1 comprising 30 from TCGA and 16 internally were used for independent validation. Based on integrated analyses of T1-weighted contrast-enhanced (T1-c) and diffusion-weighted MR images, we identified an intratumoral subregion with both high T1-c and low ADC, and accordingly defined a high-risk volume ( @entity2101 ). We evaluated its prognostic value and biological significance with genomic data. RESULTS: On both discovery and validation cohorts, @entity2101 predicted @entity1349 ( @entity1349 ) (concordance index: 0.642 and 0.653, P   <   0.001 and P   =   0.038, respectively). @entity2101 stratified @entity1 within the proneural molecular subtype (log-rank P   =   0.040, hazard ratio   =   2.787). We observed different @entity1349 among @entity1 depending on their @entity8724 methylation status and @entity2101 (log-rank P   =   0.011). @entity1 with unmethylated @entity8724 and high @entity2101 had significantly shorter survival (median survival: 9.3 vs. 18.4  months, log-rank P   =   0.002). CONCLUSION: Volume of the high-risk intratumoral subregion identified on multi-parametric MRI predicts @entity463 survival, and may provide complementary value to genomic information. KEY POINTS:     @entity2101 ( @entity2101 ) defined on multi-parametric MRI predicted @entity11 survival.     The proneural molecular subtype tended to harbour smaller @entity2101 than other subtypes.     @entity1 with unmethylated @entity8724 and high @entity2101 had significantly shorter survival.     @entity2101 complements genomic information in predicting @entity11 survival.

Volume of high-risk intratumoral subregions at multi-parametric MR imaging predicts @entity1349 and complements molecular analysis of XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer genome atlas'] @entity11 :: ('MESH:D005910', 'Disease') :: ['GBM'] @entity8724 :: ('4255', 'Gene') :: ['MGMT'] @entity2101 :: ('MESH:C538394', 'Disease') :: ['High-risk volume', 'HRV'] @entity463 :: ('MESH:D005909', 'Disease') :: ['glioblastoma', 'primary glioblastoma'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity463 :: (MESH:D005909,Disease) :: ['glioblastoma']
